Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6903800 | 0.92 | ALDH1A1 (0.48) | ALDH1A1KDM4EKMT2AMAPTMEN1 | |
| SCHEMBL16333538 | 0.85 | ALDH1A1 (0.41) | ALDH1A1KDM4EKMT2AMAPTMEN1 | |
| SCHEMBL28201234 | 0.84 | ALDH1A1 (0.47) | ALDH1A1KDM4EKMT2AMAPTMEN1 | |
| SCHEMBL16720987 | 0.84 | ALDH1A1 (0.47) | ALDH1A1KDM4EKMT2AMAPTMEN1 | |
| SCHEMBL337445 | 0.84 | PDK1 (0.50) | ALDH1A1KDM4EKMT2AMAPTMEN1 | |
| SCHEMBL15105844 | 0.84 | ALDH1A1 (0.42) | ALDH1A1KDM4EKMT2AMAPTMEN1 | |
| SCHEMBL18501426 | 0.84 | PDK1 (0.50) | ALDH1A1KDM4EKMT2AMAPTMEN1 | |
| SCHEMBL14328268 | 0.84 | PDK1 (0.50) | ALDH1A1KDM4EKMT2AMAPTMEN1 | |
| SCHEMBL1370842 | 0.83 | PPM1B (0.41) | ALDH1A1KDM4EKMT2A | |
| SCHEMBL1026276 | 0.83 | ALDH1A1 (0.47) | ALDH1A1KDM4EKMT2AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 482 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250075147-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | OSMO LABS, PBC | 2025-03-06 | — | — | US | claimed |
| CN-118561689-B | Preparation method of 3-oxo-cyclobutanecarboxylic acid ester compound | 中节能万润股份有限公司 | 2024-11-22 | — | — | CN | claimed |
| CN-117736093-A | Preparation method of 3-fluorocyclobutane carboxylic acid ethyl ester | 宿迁晨阳医药科技有限公司 | 2024-03-22 | — | — | CN | claimed |
| EP-4103557-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-02-18 | — | — | EP | disclosed |
| US-20260035335-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4673214-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2026-01-07 | — | — | EP | disclosed |
| US-20250388601-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12502378-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | JANSSEN PHARMACEUTICA NV (BE) | 2025-12-23 | — | — | US | disclosed |
| US-12492184-B2 | Heteroaryl compounds, preparation methods and uses thereof | InventisBio Co., Ltd. (CN) | 2025-12-09 | — | — | US | disclosed |
| US-12479826-B2 | Pyridazinyl amino derivatives as ALK5 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-11-25 | — | — | US | disclosed |
| US-20250313524-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-10-09 | — | — | US | disclosed |
| US-6291520-B1 | INHIBIT THE ENZYME LIPOXYGENASE; TREATMENT OR ALLEVIATION OF INFLAMMATORY DISEASES, ALLERGIC CONDITIONS AND CARDIOVASCULAR DISEASES | PFIZER | 2001-09-18 | — | — | US | disclosed |
| CN-1268937-A | Novel compound having effect of promoting neuron differentiation | NIPPON KAYAKU KK (JP) | 2000-10-04 | — | — | CN | disclosed |
| EP-0999204-A1 | NOVEL COMPOUND HAVING EFFECT OF PROMOTING NEURON DIFFERENTIATION | Nippon Kayaku Kabushiki Kaisha (JP) | 2000-05-10 | — | — | EP | disclosed |
| EP-0693054-B1 | CYCLOALKYLHYDROXYUREAS AND THEIR USE AS LIPOXYGENASE INHIBITORS | PFIZER (US) | 1998-06-10 | — | — | EP | disclosed |
| EP-0693054-A1 | CYCLOALKYLHYDROXYUREAS AND THEIR USE AS LIPOXYGENASE INHIBITORS | PFIZER INC. (US) | 1996-01-24 | — | — | EP | disclosed |
| EP-0559743-B1 | NOVEL HYDROXAMIC ACID AND N-HYDROXYUREA DERIVATIVES AND THEIR USE | PFIZER (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1994022814-A1 | CYCLOALKYLHYDROXYUREAS AND THEIR USE AS LIPOXYGENASE INHIBITORS | PFIZER INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| EP-0559743-A1 | NOVEL HYDROXAMIC ACID AND N-HYDROXYUREA DERIVATIVES AND THEIR USE. | PFIZER HOSPITAL PROD (US) | 1993-09-15 | — | — | EP | disclosed |
| WO-1992009566-A1 | NOVEL HYDROXAMIC ACID AND N-HYDROXYUREA DERIVATIVES AND THEIR USE | PFIZER INC. (US) | 1992-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313524-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CA, PIK3CB, PIK3CD | ALDH1A1 3698/4885KDM4E 2557/4885KMT2A 2974/4885 |
| US-20250388601-A1 | Compounds, Compositions and Methods | AURKC, WEE2, ERBB2 | ALDH1A1 3854/4885KDM4E 2322/4885KMT2A 1868/4885 |
| US-12502378-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | LIPC, LPL, MGLL | ALDH1A1 266/4885KDM4E 441/4885KMT2A 381/4885 |
| US-12479826-B2 | Pyridazinyl amino derivatives as ALK5 inhibitors | ALK, TGFBR1, ACVR1 | ALDH1A1 742/4885KDM4E 474/4885KMT2A 2453/4885 |
| US-20260035335-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CD, PIK3CG, PIK3CB | ALDH1A1 4597/4885KDM4E 1916/4885KMT2A 3086/4885 |
| US-12492184-B2 | Heteroaryl compounds, preparation methods and uses thereof | TYK2, IL2, IL23R | ALDH1A1 4461/4885KDM4E 3661/4885KMT2A 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.